193 related articles for article (PubMed ID: 14965331)
21. Zonisamide inhibits monoamine oxidase and enhances motor performance and social activity.
Uemura MT; Asano T; Hikawa R; Yamakado H; Takahashi R
Neurosci Res; 2017 Nov; 124():25-32. PubMed ID: 28624436
[TBL] [Abstract][Full Text] [Related]
22. Effects of zonisamide on K+ and Ca2+ evoked release of monoamine as well as K+ evoked intracellular Ca2+ mobilization in rat hippocampus.
Kawata Y; Okada M; Murakami T; Mizuno K; Wada K; Kondo T; Kaneko S
Epilepsy Res; 1999 Jul; 35(3):173-82. PubMed ID: 10413313
[TBL] [Abstract][Full Text] [Related]
23. Does levodopa slow or hasten the rate of progression of Parkinson's disease?
Fahn S;
J Neurol; 2005 Oct; 252 Suppl 4():IV37-IV42. PubMed ID: 16222436
[TBL] [Abstract][Full Text] [Related]
24. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
Chen JJ; Swope DM; Dashtipour K
Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
[TBL] [Abstract][Full Text] [Related]
25. Effects of combined administration of zonisamide and valproic acid or phenytoin to nitric oxide production, monoamines and zonisamide concentrations in the brain of seizure-susceptible EL mice.
Nagatomo I; Akasaki Y; Uchida M; Tominaga M; Hashiguchi W; Takigawa M
Brain Res Bull; 2000 Sep; 53(2):211-8. PubMed ID: 11044598
[TBL] [Abstract][Full Text] [Related]
26. Alterations of nitric oxide and monoamines in the brain of the EL mouse treated with phenobarbital and zonisamide.
Tominaga M; Nagatomo I; Uchida M; Hashiguchi W; Akasaki Y; Takigawa M
Psychiatry Clin Neurosci; 2001 Aug; 55(4):311-8. PubMed ID: 11442880
[TBL] [Abstract][Full Text] [Related]
27. Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study.
Murata M; Hasegawa K; Kanazawa I;
Neurology; 2007 Jan; 68(1):45-50. PubMed ID: 17200492
[TBL] [Abstract][Full Text] [Related]
28. Zonisamide in Parkinson's disease: a current update.
Goel A; Sugumaran R; Narayan SK
Neurol Sci; 2021 Oct; 42(10):4123-4129. PubMed ID: 34448999
[TBL] [Abstract][Full Text] [Related]
29. Zonisamide in managing impulse control disorders in Parkinson's disease.
Bermejo PE; Ruiz-Huete C; Anciones B
J Neurol; 2010 Oct; 257(10):1682-5. PubMed ID: 20509031
[TBL] [Abstract][Full Text] [Related]
30. [Effect of zonisamide on resting tremor resistant to antiparkinsonian medication].
Nakanishi I; Kohmoto J; Miwa H; Kondo T
No To Shinkei; 2003 Aug; 55(8):685-9. PubMed ID: 13677302
[TBL] [Abstract][Full Text] [Related]
31. Zonisamide.
Leppik IE
Epilepsia; 1999; 40 Suppl 5():S23-9. PubMed ID: 10530691
[TBL] [Abstract][Full Text] [Related]
32. Zonisamide: a new antiepileptic drug.
Sobieszek G; Borowicz KK; Kimber-Trojnar Z; Małek R; Piskorska B; Czuczwar SJ
Pol J Pharmacol; 2003; 55(5):683-9. PubMed ID: 14704463
[TBL] [Abstract][Full Text] [Related]
33. Zonisamide reduces nigrostriatal dopaminergic neurodegeneration in a mouse genetic model of Parkinson's disease.
Sano H; Murata M; Nambu A
J Neurochem; 2015 Jul; 134(2):371-81. PubMed ID: 25857446
[TBL] [Abstract][Full Text] [Related]
34. Zonisamide: in Parkinson's disease.
Yang LP; Perry CM
CNS Drugs; 2009 Aug; 23(8):703-11. PubMed ID: 19594199
[TBL] [Abstract][Full Text] [Related]
35. The anti-parkinsonian drug zonisamide reduces neuroinflammation: Role of microglial Na
Hossain MM; Weig B; Reuhl K; Gearing M; Wu LJ; Richardson JR
Exp Neurol; 2018 Oct; 308():111-119. PubMed ID: 30017881
[TBL] [Abstract][Full Text] [Related]
36. Pharmacological therapy of Parkinson's disease: current options and new avenues.
Simola N; Pinna A; Fenu S
Recent Pat CNS Drug Discov; 2010 Nov; 5(3):221-38. PubMed ID: 20726838
[TBL] [Abstract][Full Text] [Related]
37. Zonisamide attenuates lactacystin-induced parkinsonism in mice without affecting system x
Bentea E; Van Liefferinge J; Verbruggen L; Martens K; Kobayashi S; Deneyer L; Demuyser T; Albertini G; Maes K; Sato H; Smolders I; Lewerenz J; Massie A
Exp Neurol; 2017 Apr; 290():15-28. PubMed ID: 28024798
[TBL] [Abstract][Full Text] [Related]
38. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.
Parkinson Study Group
JAMA; 2000 Oct; 284(15):1931-8. PubMed ID: 11035889
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic role of zonisamide in neuropsychiatric disorders.
Farooq MU; Moore PW; Bhatt A; Aburashed R; Kassab MY
Mini Rev Med Chem; 2008 Sep; 8(10):968-75. PubMed ID: 18782051
[TBL] [Abstract][Full Text] [Related]
40. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
Deleu D; Hanssens Y; Northway MG
Drugs Aging; 2004; 21(11):687-709. PubMed ID: 15323576
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
